One of the most striking advances in the field is the successful targeting of HIF-2 in renal cell carcinoma, using a small molecule called PT2399, specifically designed to inhibit the binding of HIF-2α to the HIF-β subunit [242,243,244,245]. This evidence concerns the gene EPAS1 and hereditary clear cell renal cell carcinoma.